Neuronetics Reports 84% Revenue Growth Amid Increased Losses and Rising Operating Expenses

Neuronetics, Inc. (NASDAQ: STIM) - Quarterly Review (Ending March 31, 2025)

Neuronetics, Inc., a leader in neuroscience and manufacturer of the NeuroStar Advanced Therapy System, reported substantial growth in total revenues but continued to face operating losses. Here’s a concise overview of the key points from their latest earnings report:

Financial Highlights:

• Total revenues: $31.975 million for Q1 2025, up 84% from $17.417 million in Q1 2024.
• Gross profit: Increased to $15.738 million, representing a gross margin of 49.2%, down from 75.1% in the prior year.
• Net loss: Q1 2025 net loss of $12.689 million compared to $7.873 million in Q1 2024, a 61% increase in losses.
• Operating expenses: Increased to $26.752 million, up 34% year-over-year, primarily driven by additional costs from their Greenbrook acquisition.
• Cash and cash equivalents: At March 31, 2025, Neuronetics had $20.224 million, compared to $18.459 million at year-end 2024.
• Accrued expenses: Decreased from $12.818 million to $9.306 million during the quarter.

Positive Aspects:

• Significant revenue growth, particularly in clinic revenue attributable to the Greenbrook acquisition, contributing $18.7 million.
• Increase in cash reserves, suggesting improved liquidity.
• Market leadership in TMS therapy, with substantial clinical support and a growing patient base.

Negative Aspects:

• Continued net losses indicating ongoing operational challenges, primarily due to high operating costs and low gross margins.
• Decrease in gross margin as inclusion of clinic revenue diluted overall profitability.
• Higher sales and administrative expenses reflecting integration costs from the Greenbrook acquisition.

Neuronetics remains committed to enhancing their market position despite these challenges. They focus on expanding their treatment offerings and managing operational expenditures effectively.